PROCEPT BIOROBOTICS CORP
PRCTNASDAQTrading Snapshot
- Day Range
- $21.29 – $21.74
- 52-Week Range
- $16.67 – $42.71
- Volume
- $5.48B
- Avg Volume
- $4.75B
- Shares Outstanding
- 56.9M
- Next Earnings
- Oct 16, 2026
Fundamentals Snapshot
- Annual Revenue
- $308M
- Last Q Revenue
- $94M
- P/E Ratio
- —
- P/S Ratio
- 3.7x
- EPS (TTM)
- $-1.95
- Dividend Yield
- —
Why Investors Own PRCT
- ✓High-growth profile — revenue up +55.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 71% gross margin and 15% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About PROCEPT BIOROBOTICS CORP
PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH). As of year-end 2021, PROCEPT BioRobotics had successfully deployed 130 AquaBeam Robotic Systems across the globe, with a significant majority—78 units—located in the United States. Founded in 2007, the corporation maintains its headquarters in Redwood City, California.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
TD Cowen Maintains Buy on PROCEPT BioRobotics, Lowers Price Target to $28
TD Cowen analyst Joshua Jennings maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Buy and lowers the price target from $34 to $28.
Piper Sandler Maintains Overweight on PROCEPT BioRobotics, Lowers Price Target to $25
Piper Sandler analyst Matt O'Brien maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight and lowers the price target from $35 to $25.
Evercore ISI Group Maintains Outperform on PROCEPT BioRobotics, Lowers Price Target to $23
Evercore ISI Group analyst Vijay Kumar maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Outperform and lowers the price target from $30 to $23.
William Blair Downgrades PROCEPT BioRobotics to Market Perform
William Blair analyst Brandon Vazquez downgrades PROCEPT BioRobotics (NASDAQ:PRCT) from Outperform to Market Perform.
PROCEPT BioRobotics Corporation (PRCT) Q2 2026 Earnings Call Transcript
PROCEPT BioRobotics Corporation (PRCT) Q2 2026 Earnings Call August 4, 2026 4:30 PM EDTCompany ParticipantsLarry Wood - President, CEO & DirectorKevin...
Procept BioRobotics (NASDAQ:PRCT) Q2 In Line, But Unchanged Guidance Sinks Shares
PROCEPT BioRobotics Q2 revenue and EPS match estimates, but shares dip 5.8% as full-year outlook unchanged, missing Street hopes for higher guidance.